Patients with smoldering multiple myeloma derived a significant progression-free survival benefit, along with other positive outcomes, from 3 years of subcutaneous use of the monoclonal antibody darat...
Results of a phase III study suggest that the addition of the immunotherapy agent blinatumomab—a bispecific T-cell engager targeting CD19—to standard chemotherapy may help to prevent relapse in more c...
According to research reported at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition, a link seems to exist between hematologic malignancies and dietary components. The spea...
A primary analysis of ZUMA-2, reported at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition, demonstrated durable responses to brexucabtagene autoleucel in patients with Br...
First responders who worked at Ground Zero in the aftermath of the 2001 attacks on the World Trade Center in New York City were three times more likely to have genetic changes associated with an incre...
At the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 883), Alexey Danilov, MD, PhD, of the Department of Hematology & Hematopoietic Cell Transplantation at Ci...
Researchers have revealed that high-dose chemotherapy followed by autologous stem cell transplantation may not benefit patients with mantle cell lymphoma (MCL) who are in remission following initial t...
The addition of blinatumomab to chemotherapy may improve disease-free survival in pediatric patients newly diagnosed with National Cancer Institute (NCI) standard-risk B-cell acute lymphoblastic leuke...
A follow-up study investigating the coadministration of CD19- and CD22-targeted chimeric antigen receptor (CAR) T-cell therapy in children with relapsed or refractory B-cell acute lymphoblastic leukem...
Consuming a high-fiber diet after undergoing stem cell transplantation may help to reduce the risk of graft-vs-host disease (GVHD) by cultivating a healthy gut microbiome, according to research presen...
Researchers have found that the noncovalent Bruton's tyrosine kinase inhibitor (BTK) pirtobrutinib may offer superior progression-free survival in adults with chronic lymphocytic leukemia (CLL) or sma...
A combination of the oral drugs acalabrutinib and venetoclax may be more effective at improving progression-free survival and minimizing serious adverse events in patients with previously untreated ch...
Recent data suggest that a plant-based diet rich in fiber may help to improve the outlook for people with precursor conditions that can lead to multiple myeloma. The research, which involved a 12-week...
Erik Thiele Orberg, MD, PhD, of University Hospital Regensburg, shares findings of a longitudinal, prospective study investigating microbial and metabolite recovery in the post-transplant period. He d...
Hannah Choe, MD, of The Ohio State University Comprehensive Cancer Center – James Cancer Hospital, reviews results from a secondary analysis of the phase 2 AGAVE-201 study, which assessed axatilimab, ...
Natalie Wuliji, DO, and Mohamed Sorror, MD, MSc, of Fred Hutch Cancer Center and the University of Washington School of Medicine, presented results of a prospective, multicenter observational study ac...
Jenny Paredes, PhD, of City of Hope National Medical Center, discusses a study investigating the effects of dietary fiber on acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic cell...
Matthew S. Davids, MD, MMSc, of Dana-Farber Cancer Institute, Boston, discusses the primary endpoint evaluation of a phase II trial of the triplet regimen of acalabrutinib, venetoclax, and obinutuzuma...
John O. Mascarenhas, MD, of Icahn School of Medicine at Mount Sinai, discusses early results from the ongoing phase I/IB IMproveMF trial, which is evaluating the safety and activity of the novel combi...
John O. Mascarenhas, MD, of Icahn School of Medicine at Mount Sinai, discusses the results of the phase III BOREAS study evaluating the efficacy and safety of single-agent navtemadlin vs best availabl...
Timothy S. Fenske, MD, of the Medical College of Wisconsin presented an initial report from the ECOG-ACRIN EA4151 phase III randomized trial exploring outcomes of autologous hematopoietic cell transpl...
Rachel E. Rau, MD, of Seattle Children’s Hospital, and Sumit Gupta, MD, PhD, of the Hospital for Sick Children in Toronto, review results from Children’s Oncology Group Study AALL1731, which assessed ...
Nitin Jain, MD, of The University of Texas MD Anderson Cancer Center, Houston, discusses the results of a recent trial (Abstract 1011) evaluating the time-limited, combination therapy of the noncovale...
Danielle Wolfe Cohen, MD, of the William L. Carroll Laboratory at New York University Grossman School of Medicine, describes data illuminating the role of an inflammatory phenotype in driving clonal e...
Anne Sophie Michallet, MD, PhD, of Centre Léon Bérard Hospital, Lyon, France, discusses the final results of the phase II ERADIC trial (Abstract 584), which compared measurable residual disease (MRD)-...
The antibody loncastuximab tesirine may offer a benefit in patients with high-risk follicular lymphoma and marginal zone lymphoma, according to the findings of two clinical trials presented by Alderuc...
The experimental drug rilzabrutinib was well tolerated and generated an increase in platelet counts among some adults with immune thrombocytopenia (ITP) who had not experienced lasting improvements w...
An analysis of the results from the ongoing randomized phase III AQUILA study found that daratumumab monotherapy was well tolerated and demonstrated a clinically meaningful and significant benefit in ...
A large prospective observational study of patients with acute myeloid leukemia (AML) has found that lower socioeconomic status is a barrier to accessing hematopoietic cell transplantation (HCT) but ...
Findings from a series of studies conducted in mice, human tissues, and healthy volunteers suggest that a ketogenic diet may enhance the effectiveness of chimeric antigen receptor (CAR) T-cell therapy...
Jennifer R. Brown, MD, PhD, of Dana-Farber Cancer Institute, Boston, discusses the findings from the prespecified interim analysis of the phase III AMPLIFY trial (Abstract 1009), which compared fixed-...
Maayan Levy, PhD, and Marco Ruella, MD, of the University of Pennsylvania, Perelman School of Medicine, discuss findings on whether ketogenic diet-derived BHB can be provided as a dietary intervention...
Nikolaos Katsivelos, MD, and John Levine, MD, MS, of Icahn School of Medicine at Mount Sinai report on an investigation into the potential for serial monitoring of graft-versus-host disease (GVHD) sym...
Jennifer R. Brown, MD, PhD, of Dana-Farber Cancer Institute, Boston, discusses the findings from the prespecified interim analysis of the phase III AMPLIFY trial (Abstract 1009), which compared fixed-...
The American Society of Hematology (ASH) honored Rep. Michael Burgess, MD (R-TX) and Centers for Disease Control and Prevention (CDC) health scientist Mary Hulihan, DrPH, for their leadership on is...
The American Society of Hematology (ASH) will recognize exemplary hematologists who have made significant contributions to the field with several honorific awards at the 2024 ASH Annual Meeting and Ex...